CAS 17316-67-5: P-[1-(Butylamino)-1-methylethyl]phosphinic acid

Butafosfan, often with cyanocobalamin, boosts lipid metabolism in livestock to prevent/treat deficiencies and ketosis.

[1-(Butylamino)-1-methyl-ethyl]phosphinic acid

Stability Hygroscopic Applications Butafosfan, a component of Catosal, is licensed for the treatment of metabolic disorders or as a tonic in swine. It reduces the stress-induced cortisol (C696302, d4 labelled) response after mixing of unfamiliar pigs. It can also increase milk production in Holstein cows in combination with cyanocobalamin. References De Groot, J., et al.: J. Vet. Pharmacol. Ther., 26, 222 (2003); Pereira, R., et al.: Animal, 7, 1143 (2013)

Butaphosphan is a drug that has been shown to have clinical relevance for the treatment of metabolic disorders. It is a prodrug that is converted into butaprost-diol, which has been shown to improve insulin sensitivity and reduce aminotransferase activity in rats. Butaphosphan can be used as an alternative to aminotransferase inhibitors such as ursodeoxycholic acid and cholestyramine for the treatment of patients with primary biliary cirrhosis. This drug has also been shown to have a protective effect on fatty acid metabolism, which may be due to its ability to inhibit the activity of enzymes involved in fatty acid synthesis. Butaphosphan is metabolized by cytochrome P450 enzymes and hydroxylases and can be detected using LC-MS/MS methods. The drug has also been shown to have beneficial effects on cortisol concentrations and liver histology when administered orally.